Tumor News and Research

RSS

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Three-drug regimen provides rapid, durable responses for multiple myeloma

A three-drug treatment for the blood cancer multiple myeloma provided rapid, deep and potentially durable responses, researchers report today online in Blood, the Journal of the American Society of Hematology, and yesterday, Sunday, June 3, 2012, at the American Society of Clinical Oncology's Annual Meeting in Chicago, IL, USA.

5 Jun 2012

T-DM1 better than standard therapy in controlling breast cancer

A new cancer treatment that links chemotherapy with an agent that homes in on specific breast cancer cells was significantly better than the current drug regimen at keeping patients' advanced tumors from progressing, according to results from a Phase III clinical trial led by Kimberly Blackwell, M.D., of the Duke Cancer Institute.

5 Jun 2012

New PD-1 blocking antibody shows promise against advanced kidney cancer

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

5 Jun 2012

Updated results from three trials of Bruton's ibrutinib for treatment of CLL/SLL

Pharmacyclics, Inc announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

5 Jun 2012

Survivors of childhood cancers are at increased risk for GI cancers

Survivors of childhood cancers are at an increased risk of another battle with cancer later in life, according to new research published online June 4 by the Annals of Internal Medicine. In the largest study to date of risk for gastrointestinal (GI) cancers among people first diagnosed with cancer before the age of 21, researchers found that childhood cancer survivors develop these malignancies at a rate nearly five times that of the general population.

5 Jun 2012

Study detects significant changes in the EEG brain activity patterns during chemotherapy

A Cleveland Clinic study has detected significant changes in the electroencephalogram (EEG) brain activity patterns of patients receiving chemotherapy.

5 Jun 2012

Preoperative breast cancer pain involves an inflammatory process

Researchers from the University of California San Francisco studied a sample of women scheduled for breast cancer surgery and sought to determine the occurrence rate for preoperative breast pain, describe characteristics of the pain, evaluate the demographic and clinical variation in the women with preoperative pain, and assess the role of in pro-and anti inflammatory cytokine genes.

5 Jun 2012

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.

5 Jun 2012

Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting

Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

5 Jun 2012

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Senesco Technologies, Inc. reported today on the progress of its Phase 1b/2a study for the treatment of multiple myeloma, which is the subject of a poster presented today at the 2012 Annual Meeting of the American Society of Clinical Oncology.

5 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

Researchers uncover cellular basis for age-related breast cancer vulnerability

It is well-known that the risks of breast cancer increase dramatically for women over the age of 50, but what takes place at the cellular level to cause this increase has been a mystery. Some answers and the possibility of preventative measures in the future are provided in a new study by researchers at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory.

5 Jun 2012

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

Promising data on MEK162 in an ongoing Phase 2 trial of patients with BRAF and NRAS mutated advanced melanoma was presented today at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

Advaxis to update preliminary data on ADXS-HPV Phase 2 trial for cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, will update preliminary data on the safety and clinical benefit of ADXS-HPV from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer who have failed cytotoxic therapy in a poster titled "ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer" at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, on Sunday, June 3, 2012.

4 Jun 2012

Tumor News and Research

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Three-drug regimen provides rapid, durable responses for multiple myeloma

T-DM1 better than standard therapy in controlling breast cancer

New PD-1 blocking antibody shows promise against advanced kidney cancer

Updated results from three trials of Bruton's ibrutinib for treatment of CLL/SLL

Survivors of childhood cancers are at increased risk for GI cancers

Study detects significant changes in the EEG brain activity patterns during chemotherapy

Preoperative breast cancer pain involves an inflammatory process

Jennerex announces data from JX-594 clinical studies on cancer

Esperance presents results from EP-100 Phase 1 study on solid tumors at ASCO annual meeting

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Senesco reports on the progress of SNS01-T Phase 1b/2a study for multiple myeloma

Exelixis reports data from cabozantinib phase 3 trial on MTC

Researchers uncover cellular basis for age-related breast cancer vulnerability

Promising data from Array BioPharma’s MEK162 Phase 2 trial on BRAF and NRAS mutant melanoma

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Advaxis to update preliminary data on ADXS-HPV Phase 2 trial for cervical cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News